Works matching IS 13866346 AND DT 2021 AND VI 51 AND IP 9


Results: 10
    1
    2
    3
    4
    5

    Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.

    Published in:
    Hepatology Research, 2021, v. 51, n. 9, p. 979, doi. 10.1111/hepr.13693
    By:
    • Sho, Takuya;
    • Suda, Goki;
    • Ogawa, Koji;
    • Kimura, Megumi;
    • Kubo, Akinori;
    • Tokuchi, Yoshimasa;
    • Kitagataya, Takashi;
    • Maehara, Osamu;
    • Ohnishi, Shunsuke;
    • Shigesawa, Taku;
    • Nakamura, Akihisa;
    • Yamada, Ren;
    • Ohara, Masatsugu;
    • Kawagishi, Naoki;
    • Natsuizaka, Mitsuteru;
    • Nakai, Masato;
    • Morikawa, Kenichi;
    • Furuya, Ken;
    • Baba, Masaru;
    • Yamamoto, Yoshiya
    Publication type:
    Article
    6
    7
    8
    9

    Issue Information.

    Published in:
    Hepatology Research, 2021, v. 51, n. 9, p. 919, doi. 10.1111/hepr.13521
    Publication type:
    Article
    10

    aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C.

    Published in:
    Hepatology Research, 2021, v. 51, n. 9, p. 933, doi. 10.1111/hepr.13689
    By:
    • Yamashita, Yuki;
    • Joshita, Satoru;
    • Sugiura, Ayumi;
    • Yamazaki, Tomoo;
    • Kobayashi, Hiroyuki;
    • Wakabayashi, Shun‐ichi;
    • Yamada, Yosuke;
    • Shibata, Soichiro;
    • Kunimoto, Hideo;
    • Iwadare, Takanobu;
    • Matsumura, Makiko;
    • Miyabayashi, Chiharu;
    • Okumura, Taiki;
    • Ozawa, Sachie;
    • Nozawa, Yuichi;
    • Kobayashi, Natsuko;
    • Komatsu, Michiharu;
    • Fujimori, Naoyuki;
    • Saito, Hiromi;
    • Umemura, Takeji
    Publication type:
    Article